| 2298 | Humans |
| 1353 | Parkinson disease |
| 1337 | Male |
| 1282 | Female |
| 994 | Middle Aged |
| 991 | Aged |
| 812 | Human |
| 700 | Animals |
| 638 | Parkinson Disease (physiopathology) |
| 637 | Nervous system diseases |
| 499 | Adult |
| 464 | Parkinson Disease (drug therapy) |
| 326 | Parkinson Disease (complications) |
| 290 | Parkinson Disease (metabolism) |
| 290 | Aged, 80 and over |
| 285 | Treatment |
| 279 | Parkinson Disease (pathology) |
| 251 | Parkinson Disease (therapy) |
| 244 | Parkinson Disease (diagnosis) |
| 215 | Parkinson's disease |
| 210 | Animal |
| 201 | Parkinson Disease (genetics) |
| 199 | Dopamine |
| 193 | Antiparkinson Agents (therapeutic use) |
| 188 | Parkinson Disease (psychology) |
| 179 | Levodopa (therapeutic use) |
| 173 | Rats |
| 167 | Case-Control Studies |
| 166 | Dopamine (metabolism) |
| 154 | Treatment Outcome |
| 152 | Disease Models, Animal |
| 150 | Mice |
| 144 | Severity of Illness Index |
| 143 | Parkinson Disease (epidemiology) |
| 140 | Chemotherapy |
| 139 | Levodopa |
| 132 | Time Factors |
| 128 | Antiparkinson agent |
| 125 | Rat |
| 124 | Neuropsychological Tests |
| 122 | Brain (metabolism) |
| 117 | Brain (pathology) |
| 114 | Parkinson Disease (surgery) |
| 114 | Degenerative disease |
| 113 | Parkinson Disease, Secondary (chemically induced) |
| 112 | Parkinson Disease (diagnostic imaging) |
| 112 | Dyskinesia |
| 111 | Levodopa (adverse effects) |
| 105 | Exploration |
| 105 | Corpus striatum |
| 104 | Antiparkinson Agents (adverse effects) |
| 101 | Risk Factors |
| 101 | Follow-Up Studies |
| 101 | Brain (physiopathology) |
| 98 | Review |
| 98 | Disease Progression |
| 98 | Canada |
| 97 | Analysis of Variance |
| 95 | Toxicity |
| 94 | Parkinson Disease (etiology) |
| 91 | Magnetic Resonance Imaging |
| 90 | Basal ganglion |
| 87 | Monkey |
| 86 | Alzheimer disease |
| 83 | Immunohistochemistry |
| 83 | Deep Brain Stimulation (methods) |
| 82 | Subthalamic nucleus |
| 80 | Retrospective Studies |
| 79 | Adolescent |
| 75 | Neurons (metabolism) |
| 74 | Tomography, Emission-Computed |
| 74 | Emission tomography |
| 73 | Parkinsonism |
| 73 | Corpus Striatum (metabolism) |
| 73 | Cognition |
| 72 | Cohort Studies |
| 71 | Deep brain stimulation |
| 70 | Dose-Response Relationship, Drug |
| 70 | Comparative study |
| 69 | Macaca fascicularis |
| 68 | Reproducibility of Results |
| 68 | Mutation |
| 67 | Psychomotor Performance (physiology) |
| 66 | Tremor |
| 66 | Prevalence |
| 66 | Movement (physiology) |
| 64 | Surgery |
| 64 | Rats, Sprague-Dawley |
| 64 | Animal model |
| 62 | Neurons (physiology) |
| 62 | Encephalon |
| 62 | Age Factors |
| 61 | Pathogenesis |
| 59 | Wolff Parkinson White syndrome |
| 59 | Pathophysiology |
| 59 | Elderly |
| 59 | Double-Blind Method |
| 59 | Dopamine (physiology) |
| 58 | Electrocardiography |
| 58 | Brain (vertebrata) |
| 56 | Wolff-Parkinson-White Syndrome (physiopathology) |
| 56 | Pallidum |
| 56 | Mouse |
| 55 | Locus niger |
| 55 | Electromyography |
| 54 | Wolff-Parkinson-White Syndrome (surgery) |
| 54 | Surveys and Questionnaires |
| 54 | Substantia Nigra (pathology) |
| 54 | Prognosis |
| 54 | Neurons (drug effects) |
| 54 | Child |
| 52 | Quality of Life |
| 52 | Mice, Inbred C57BL |
| 52 | D2 Dopamine receptor |
| 52 | Cognitive disorder |
| 52 | Cognition Disorders (etiology) |
| 51 | Cells, Cultured |
| 51 | Brain Mapping |
| 51 | Behavior |
| 50 | Diagnosis, Differential |
| 49 | Tremor (physiopathology) |
| 49 | Positron emission tomography |
| 49 | Experimental disease |
| 49 | Brain (diagnostic imaging) |
| 49 | Agonist |
| 48 | Molecular Sequence Data |
| 48 | Models, Biological |
| 48 | Dopaminergic neuron |
| 47 | Reference Values |
| 47 | Prospective Studies |
| 47 | Nuclear magnetic resonance imaging |
| 47 | Neurotoxin |
| 47 | Neurons (pathology) |
| 47 | Globus Pallidus (surgery) |
| 47 | Complication |
| 46 | alpha-Synuclein (metabolism) |
| 46 | Parkinson Disease, Secondary (physiopathology) |
| 46 | Diagnosis |
| 46 | Brain (drug effects) |
| 45 | Neuron |
| 45 | Levodopa (pharmacology) |
| 45 | Dopamine agonist |
| 45 | Dementia |
| 45 | Corpus Striatum (drug effects) |
| 45 | Antiparkinson Agents (pharmacology) |
| 44 | Positron-Emission Tomography |
| 44 | Electrodiagnosis |
| 44 | Dyskinesia, Drug-Induced (physiopathology) |
| 43 | Positron |
| 43 | Central nervous system |
| 42 | Subthalamic Nucleus (physiology) |
| 42 | Mutation (genetics) |
| 42 | Motor control |
| 42 | Dopamine Agents (therapeutic use) |
| 41 | Reaction Time (physiology) |
| 41 | Magnetic Resonance Imaging (methods) |
| 41 | Antiparkinson Agents (administration & dosage) |
| 41 | Amino Acid Sequence |
| 41 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine |
| 40 | Motor Activity (drug effects) |
| 40 | Globus Pallidus (physiopathology) |
| 40 | Case study |
| 39 | Subthalamic Nucleus (physiopathology) |
| 39 | Substantia Nigra (drug effects) |
| 39 | Risk factor |
| 39 | Protein-Serine-Threonine Kinases (genetics) |
| 39 | Predictive Value of Tests |
| 39 | Phenotype |
| 39 | Genotype |
| 39 | Disability Evaluation |
| 39 | Cross-Sectional Studies |
| 39 | Arrhythmia |
| 38 | Young Adult |
| 38 | Electrophysiology |
| 38 | Cardiovascular disease |
| 38 | Biomechanical Phenomena |
| 38 | Behavior, Animal (drug effects) |
| 37 | United States |
| 37 | Sensitivity and Specificity |
| 37 | Longitudinal Studies |
| 37 | Depression |
| 37 | Alzheimer Disease (pathology) |
| 37 | Algorithms |
| 36 | Tyrosine 3-Monooxygenase (metabolism) |
| 36 | Levodopa (administration & dosage) |
| 36 | Image Processing, Computer-Assisted |
| 36 | Epidemiology |
| 36 | Dopamine receptor |
| 36 | Body movement |
| 35 | dopamine |
| 35 | Technique |
| 35 | Psychiatric Status Rating Scales |
| 35 | Parkinson Disease, Secondary (pathology) |
| 35 | Mechanism of action |
| 35 | Long term |
| 35 | Dyskinesia, Drug-Induced (etiology) |
| 35 | Cognition Disorders (diagnosis) |
| 35 | Autoradiography |
| 34 | Tremor (etiology) |
| 34 | Posture |
| 34 | Leucine-Rich Repeat Serine-Threonine Protein Kinase-2 |
| 34 | Dihydroxyphenylalanine (analogs & derivatives) |
| 34 | Deep Brain Stimulation |
| 34 | Corpus Striatum (diagnostic imaging) |
| 34 | Clinical Trials as Topic |
| 34 | Age of Onset |
| 34 | Activities of Daily Living |
| 33 | Ubiquitin-Protein Ligases (metabolism) |
| 33 | Oxidative stress |
| 33 | Mice, Knockout |
| 33 | Genetics |
| 33 | Functional Laterality (physiology) |
| 33 | Electroencephalography |
| 33 | Drug Therapy, Combination |
| 33 | Alzheimer Disease (metabolism) |
| 32 | Substantia Nigra (physiopathology) |
| 32 | Psychomotor Performance |
| 32 | Parkinson Disease, Secondary (metabolism) |
| 32 | Parkinson Disease (rehabilitation) |
| 32 | Oxidopamine |
| 32 | Neuroprotective Agents (therapeutic use) |
| 32 | Dopamine Agonists (therapeutic use) |
| 32 | Dopa |
| 32 | Degeneration |
| 31 | deep brain stimulation |
| 31 | Ubiquitin-Protein Ligases (genetics) |
| 31 | Psychotropic |
| 31 | Positron-Emission Tomography (methods) |
| 31 | Parkinson Disease, Secondary (drug therapy) |
| 31 | Parkinson Disease (enzymology) |
| 31 | Instrumentation therapy |
| 31 | Dopamine Agents (pharmacology) |
| 31 | Canada (epidemiology) |
| 30 | alpha-Synuclein (genetics) |
| 30 | Substantia Nigra (metabolism) |
| 30 | Sleep disorder |
| 30 | Psychomotor Performance (drug effects) |
| 30 | Neural Pathways (physiopathology) |
| 30 | Motor system disorder |
| 30 | Motor Activity (physiology) |
| 30 | Genetic Predisposition to Disease |
| 30 | Functional Laterality |
| 30 | Electrodes, Implanted |
| 30 | Dementia (pathology) |
| 30 | Corpus Striatum (physiopathology) |
| 30 | Basal Ganglia (physiopathology) |
| 29 | Wolff-Parkinson-White Syndrome (diagnosis) |
| 29 | Thalamus |
| 29 | Sex Factors |
| 29 | Models |
| 29 | Inflammation |
| 29 | Incidence |
| 29 | In vitro |
| 29 | Electrical stimulus |
| 29 | Brain |
| 28 | Rapid eye movement sleep |
| 28 | Psychosis |
| 28 | Neurologic Examination |
| 28 | Mitochondria (metabolism) |
| 28 | Mice, Transgenic |
| 28 | Lesion |
| 28 | Huntington disease |
| 28 | Heart Conduction System (physiopathology) |
| 28 | Gait Disorders, Neurologic (etiology) |
| 28 | Corpus Striatum (pathology) |
| 28 | Autopsy |
| 27 | Statistics, Nonparametric |
| 27 | Neuroprotective Agents (pharmacology) |
| 27 | Motor Cortex (physiopathology) |
| 27 | Models, Neurological |
| 27 | Idiopathic |
| 27 | Gait |
| 27 | Evolution |
| 27 | Dopaminergic Neurons (metabolism) |
| 27 | Cell Line |
| 27 | Apoptosis |
| 26 | Transplantation |
| 26 | Pilot Projects |
| 26 | Nigrostriatal pathway |
| 26 | Microelectrodes |
| 26 | Metabolism |
| 26 | Dopamine Plasma Membrane Transport Proteins (metabolism) |
| 26 | D1 Dopamine receptor |
| 26 | Adenosine (metabolism) |
| 26 | Action Potentials (physiology) |
| 26 | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (pharmacology) |
| 25 | Senescence |
| 25 | Schizophrenia |
| 25 | Putamen (metabolism) |
| 25 | Phylogeny |
| 25 | Pathology |
| 25 | Movement Disorders (physiopathology) |
| 25 | Motor Activity |
| 25 | Electric Stimulation Therapy |
| 25 | Dystonia |
| 25 | Dopamine Agonists (pharmacology) |
| 25 | Cognition (physiology) |
| 24 | Stereotaxic Techniques |
| 24 | REM Sleep Behavior Disorder (diagnosis) |
| 24 | Public health |
| 24 | Posture (physiology) |
| 24 | Motricity |
| 24 | Instrumental stimulation |
| 24 | Guam Parkinson dementia |
| 24 | Dyskinesia, Drug-Induced (metabolism) |
| 24 | Dyskinesia, Drug-Induced (drug therapy) |
| 24 | Dementia (etiology) |
| 23 | dyskinesia |
| 23 | Randomized Controlled Trials as Topic |
| 23 | Protein Binding |
| 23 | Primates |
| 23 | Polysomnography |
| 23 | Neural Pathways (physiology) |
| 23 | Memory |
| 23 | Environment |
| 23 | Dopamine Agonists (adverse effects) |
| 23 | Dopamine Agents (adverse effects) |
| 23 | Comorbidity |
| 23 | Cell death |
| 23 | Brain (physiology) |
| 23 | Base Sequence |
| 23 | Astrocyte |
| 23 | Antipsychotic Agents (therapeutic use) |
| 22 | Receptors, Dopamine (drug effects) |
| 22 | Raclopride |
| 22 | REM Sleep Behavior Disorder (complications) |
| 22 | Postural Balance (physiology) |
| 22 | Pedigree |
| 22 | Lewy Bodies (pathology) |
| 22 | Kinetics |
| 22 | Etiology |
| 22 | Cerebral Cortex (physiopathology) |
| 22 | Cell Line, Tumor |
| 22 | Blotting, Western |
| 22 | Astrocytes (metabolism) |
| 22 | Antipsychotic Agents (adverse effects) |
| 22 | Amyotrophic lateral sclerosis |
| 21 | Treatment efficiency |
| 21 | Symptomatology |
| 21 | Signal Transduction |
| 21 | Receptors, Dopamine (metabolism) |
| 21 | RNA, Messenger (metabolism) |
| 21 | Parkinson Disease (classification) |
| 21 | Oxidative Stress |
| 21 | Ontario |
| 21 | Movement Disorders (etiology) |
| 21 | Motor Cortex (physiology) |
| 21 | Heart Conduction System (surgery) |
| 21 | Gene expression |
| 21 | Gait Disorders, Neurologic (physiopathology) |
| 21 | Fluorine Radioisotopes |
| 21 | Biological activity |
| 21 | Basal Ganglia (pathology) |
| 21 | Alzheimer Disease (diagnosis) |
| 21 | Accessory bundle |
| 20 | rat |
| 20 | Wolff-Parkinson-White Syndrome (complications) |
| 20 | Regression Analysis |
| 20 | Psychometrics |
| 20 | Parkinson Disease (mortality) |
| 20 | Neuroprotective agent |
| 20 | Movement |
| 20 | Mitochondria |
| 20 | Microelectrode |
| 20 | History, 20th Century |
| 20 | Gait (physiology) |
| 20 | Executive function |
| 20 | Dopamine Plasma Membrane Transport Proteins |
| 20 | Data Interpretation, Statistical |
| 20 | Brain Mapping (methods) |
| 20 | Attention |
| 19 | Walking |
| 19 | REM Sleep Behavior Disorder (physiopathology) |
| 19 | Putamen |
| 19 | Prevention |
| 19 | Placebo Effect |
| 19 | Photic Stimulation |
| 19 | Parkinson Disease |
| 19 | Parkinson Disease (blood) |
| 19 | Neuroleptic |
| 19 | Movement (drug effects) |
| 19 | Midbrain |
| 19 | Lewy body |
| 19 | Iron |
| 19 | Gene Expression Regulation |
| 19 | Electric Stimulation |
| 19 | Catecholamine |
| 19 | Biological receptor |
| 19 | Alzheimer Disease (physiopathology) |
| 18 | levodopa |
| 18 | Vision |
| 18 | Statistics as Topic |
| 18 | Signal Transduction (physiology) |
| 18 | Selegiline (therapeutic use) |
| 18 | Reward |
| 18 | Reaction Time |
| 18 | Protein Kinases (genetics) |
| 18 | Pregnancy |
| 18 | Perception |
| 18 | Parkinson Disease (immunology) |
| 18 | Muscle, Skeletal (physiopathology) |
| 18 | Medical screening |
| 18 | MPTP |
| 18 | Learning |
| 18 | In vivo |
| 18 | HEK293 Cells |
| 18 | Gene |
| 18 | Evoked Potentials, Motor (physiology) |
| 18 | Dyskinesia, Drug-Induced (prevention & control) |
| 18 | Drug Combinations |
| 18 | Dementia (diagnosis) |
| 18 | Dementia (complications) |
| 18 | Cognition Disorders (physiopathology) |
| 18 | Cerebral disorder |
| 18 | Cell Count |
| 18 | Cardiac Pacing, Artificial |
| 18 | Binding Sites |
| 18 | Alzheimer's disease |
| 17 | Tremor (therapy) |
| 17 | Tomography, Emission-Computed, Single-Photon |
| 17 | Thalamus (physiopathology) |
| 17 | Task Performance and Analysis |
| 17 | Syndrome |
| 17 | Stereotaxic surgery |
| 17 | Risk |
| 17 | Reverse Transcriptase Polymerase Chain Reaction |
| 17 | Receptors, Dopamine D2 (metabolism) |
| 17 | Receptors, Dopamine (physiology) |
| 17 | Radionuclide study |
| 17 | Quebec |
| 17 | Protein Structure, Tertiary |
| 17 | Protein Kinases (metabolism) |
| 17 | Proportional Hazards Models |
| 17 | Postoperative Complications |
| 17 | Phosphorylation |
| 17 | Parkinson’s disease |
| 17 | Parkinsonian Disorders (physiopathology) |
| 17 | Oscillation |
| 17 | Neuroprotection |
| 17 | Neurodegenerative Diseases (pathology) |
| 17 | Nerve Tissue Proteins |
| 17 | Motor cortex |
| 17 | Motor Skills (physiology) |
| 17 | Memory (physiology) |
| 17 | Membrane Glycoproteins |
| 17 | Infant |
| 17 | In Vitro Techniques |
| 17 | Dopaminergic pathway |
| 17 | Depression (etiology) |
| 17 | DNA Mutational Analysis |
| 17 | Cues |
| 17 | Computer Simulation |
| 17 | Chronic |
| 17 | Catheter Ablation |
| 17 | Carbidopa (therapeutic use) |
| 17 | Antagonist |
| 17 | Aging (physiology) |
| 16 | genetics |
| 16 | Tremor (diagnosis) |
| 16 | Thioinosine (analogs & derivatives) |
| 16 | Subthalamic Nucleus (surgery) |
| 16 | Signal Processing, Computer-Assisted |
| 16 | Sensitivity |
| 16 | Reactive Oxygen Species (metabolism) |
| 16 | Rats, Long-Evans |
| 16 | Radiopharmaceuticals |
| 16 | Parkinson Disease (prevention & control) |
| 16 | Pain |
| 16 | Oral administration |
| 16 | Nerve Tissue Proteins (genetics) |
| 16 | Movement Disorders (therapy) |
| 16 | Models, Statistical |
| 16 | Modeling |
| 16 | Memory disorder |
| 16 | Membrane Transport Proteins |
| 16 | Logistic Models |
| 16 | Locomotion |
| 16 | Involuntary movement |
| 16 | Glutamate receptor |
| 16 | Genetic Predisposition to Disease (genetics) |
| 16 | Extrapyramidal syndrome |
| 16 | Electrodes |
| 16 | Dysfunction |
| 16 | Drug Administration Schedule |
| 16 | Drosophila Proteins (genetics) |
| 16 | Dopaminergic Neurons (pathology) |
| 16 | Deep Brain Stimulation (adverse effects) |
| 16 | Clinical trial |
| 16 | Cerebral Cortex (pathology) |
| 16 | Cell Survival |
| 16 | Caudate Nucleus (metabolism) |
| 16 | Catheter Ablation (methods) |
| 16 | Carbon Radioisotopes |
| 16 | Brain Chemistry |
| 16 | Basal Ganglia (physiology) |
| 16 | Basal Ganglia (metabolism) |
| 16 | Attention (physiology) |
| 16 | Alzheimer Disease (drug therapy) |
| 15 | parkinsonism |
| 15 | basal ganglia |
